OptimizeRx Corp. will discuss Q3 2025 results in a conference call on November 6, 2025.
Quiver AI Summary
OptimizeRx Corp. will conduct a conference call on November 6, 2025, at 4:30 p.m. ET to discuss its third-quarter financial results for the period ending September 30, 2025. Prior to the call, the company will release its financial results and the call will be hosted by the management team with a question-and-answer session afterward. Interested participants can access the call via a toll-free number or a web link provided in the release. A replay will be available on the company's investor website for 12 months. OptimizeRx specializes in healthcare technology that connects life science brands with healthcare professionals and patients, utilizing innovative tools for effective marketing and improved patient outcomes. The company is headquartered in Waltham, Massachusetts.
Potential Positives
- OptimizeRx will discuss its third quarter financial results in a conference call, which provides an opportunity for transparency and engagement with stakeholders.
- The company leverages advanced technology like AI-driven tools and micro-targeting strategies, indicating a strong commitment to innovation in healthcare marketing.
- OptimizeRx highlights its partnerships with leading pharmaceutical and life sciences companies, reinforcing its position as a key player in transforming the healthcare landscape.
Potential Negatives
- Announcement of a conference call may indicate that the company is preparing to disclose results that could reflect poorly on its financial performance.
- Potential concerns regarding the need for a Q&A session may suggest transparency issues or challenges the company anticipates in addressing investor or analyst inquiries.
- Use of technical jargon and industry-specific terminology might alienate non-expert stakeholders who are interested in company performance.
FAQ
What is the date and time of the OptimizeRx conference call?
The conference call is scheduled for Thursday, November 6, 2025, at 4:30 p.m. Eastern Time.
How can I access the OptimizeRx conference call?
You can dial 1-844-825-9789 for toll-free access or 1-412-317-5180 for international calls.
Where can I find the financial results for OptimizeRx's Q3 2025?
The financial results will be issued in a press release prior to the conference call on November 6, 2025.
Is there a replay available for the OptimizeRx conference call?
Yes, a replay of the call will be available for 12 months on the Investors section of the OptimizeRx website.
What technology solutions does OptimizeRx provide?
OptimizeRx offers AI-driven tools like the Dynamic Audience Activation Platform and Micro-Neighborhood Targeting for healthcare marketing.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OPRX Insider Trading Activity
$OPRX insiders have traded $OPRX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $OPRX stock by insiders over the last 6 months:
- PATRICK D SPANGLER sold 11,120 shares for an estimated $194,488
- STEPHEN L SILVESTRO (Chief Executive Officer) sold 1,620 shares for an estimated $30,375
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OPRX Hedge Fund Activity
We have seen 64 institutional investors add shares of $OPRX stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- INVESCO LTD. removed 293,554 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,962,979
- MANATUCK HILL PARTNERS, LLC added 265,000 shares (+139.5%) to their portfolio in Q2 2025, for an estimated $3,577,500
- ROYCE & ASSOCIATES LP removed 203,660 shares (-20.5%) from their portfolio in Q2 2025, for an estimated $2,749,410
- BALYASNY ASSET MANAGEMENT L.P. added 156,338 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,110,563
- MARSHALL WACE, LLP removed 139,165 shares (-55.4%) from their portfolio in Q2 2025, for an estimated $1,878,727
- JANNEY MONTGOMERY SCOTT LLC removed 124,751 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,684,138
- SCHONFELD STRATEGIC ADVISORS LLC added 121,619 shares (+99.7%) to their portfolio in Q2 2025, for an estimated $1,641,856
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OPRX Analyst Ratings
Wall Street analysts have issued reports on $OPRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 10/10/2025
- Stifel issued a "Buy" rating on 08/08/2025
To track analyst ratings and price targets for $OPRX, check out Quiver Quantitative's $OPRX forecast page.
$OPRX Price Targets
Multiple analysts have issued price targets for $OPRX recently. We have seen 2 analysts offer price targets for $OPRX in the last 6 months, with a median target of $20.5.
Here are some recent targets:
- Constantine Davides from JMP Securities set a target price of $23.0 on 10/10/2025
- David Grossman from Stifel set a target price of $18.0 on 08/08/2025
Full Release
WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call.
OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:
| Date: | Thursday, November 6, 2025 |
| Time: | 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) |
| Toll Free: | 1-844-825-9789 |
| International: | 1-412-317-5180 |
| Conference ID: | 10203796 |
| Call me™ Link: | https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg== |
| Call me™ Passcode: | 1758869 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1738663&tp_key=cbe79a5b8d |
Please call the conference telephone number or log on to the web access link five minutes prior to the start time.
A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at http://www.optimizerx.com/investors .
About OptimizeRx
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com .
OptimizeRx Contact
Andy D’Silva, Chief Business Officer
[email protected]
Investor Relations Contact
Steven Halper
LifeSci Advisors, LLC
[email protected]
